Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05244408

"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation

Status
Recruiting
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
University of British Columbia · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

Prospective, single center study designed to assess blood biomarkers for classifying injury severity and predict neurologic recovery in traumatic spinal cord injured (SCI) patients. Study will also establish the accuracy of point to care devices for SCI blood biomarkers and support the biospecimen collection for the International Spinal Cord Injury Biobank (ISCIB).

Detailed description

This single center study at Vancouver General Hospital (VGH) will enroll patients with acute traumatic cervical and thoracic SCI who will have blood samples obtained daily for the first week post-injury. They will then have follow-up neurologic assessments at 6 and 12 months post-injury. The specific aims of the study are to: 1. Validate serum Neurofilament Light Chain (NF-L) and Glial Fibrillary Acidic Protein (GFAP) as biomarkers of acute SCI for classifying injury severity and predicting neurologic recovery. 2. Establish the relationship between serum and plasma levels of NF-L and GFAP. 3. Establish the accuracy of point-of-care devices for measuring GFAP. 4. Support biospecimen collection for the International Spinal Cord Injury Biobank (ISCIB).

Conditions

Timeline

Start date
2023-03-17
Primary completion
2025-05-30
Completion
2026-05-30
First posted
2022-02-17
Last updated
2023-07-03

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05244408. Inclusion in this directory is not an endorsement.